Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Dexcom Inc (NASDAQ: DXCM) was $134.00 for the day, up 1.89% from the previous closing price of $131.52. In other words, the price has increased by $1.89 from its previous closing price. On the day, 2.01 million shares were traded. DXCM stock price reached its highest trading level at $135.31 during the session, while it also had its lowest trading level at $131.0.
Ratios:
Our analysis of DXCM’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 100.91. For the most recent quarter (mrq), Quick Ratio is recorded 2.48 and its Current Ratio is at 2.84. In the meantime, Its Debt-to-Equity ratio is 1.25 whereas as Long-Term Debt/Eq ratio is at 1.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $165.
Raymond James Upgraded its Outperform to Strong Buy on April 17, 2023, whereas the target price for the stock was revised from $127 to $138.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 15 ’24 when Dolan Matthew Vincent sold 1,990 shares for $137.81 per share. The transaction valued at 274,242 led to the insider holds 42,377 shares of the business.
SAYER KEVIN R sold 49,633 shares of DXCM for $6,864,136 on Apr 08 ’24. The President CEO and Chairman now owns 283,893 shares after completing the transaction at $138.30 per share. On Mar 28 ’24, another insider, Brown Michael Jon, who serves as the EVP Chief Legal Officer of the company, sold 2,624 shares for $140.04 each. As a result, the insider received 367,472 and left with 68,682 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 53067481088 and an Enterprise Value of 50572890112. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 102.24, and their Forward P/E ratio for the next fiscal year is 59.89. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.06. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.26 while its Price-to-Book (P/B) ratio in mrq is 24.97. Its current Enterprise Value per Revenue stands at 13.962 whereas that against EBITDA is 64.531.
Stock Price History:
Over the past 52 weeks, DXCM has reached a high of $142.00, while it has fallen to a 52-week low of $74.75. The 50-Day Moving Average of the stock is 3.49%, while the 200-Day Moving Average is calculated to be 16.49%.
Shares Statistics:
DXCM traded an average of 3.03M shares per day over the past three months and 2422390 shares per day over the past ten days. A total of 385.40M shares are outstanding, with a floating share count of 377.42M. Insiders hold about 2.10% of the company’s shares, while institutions hold 99.33% stake in the company. Shares short for DXCM as of 1711584000 were 14572039 with a Short Ratio of 4.80, compared to 1709164800 on 16648248. Therefore, it implies a Short% of Shares Outstanding of 14572039 and a Short% of Float of 4.279999999999999.
